Cerebrospinal Fluid Stanniocalcin-1 As a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders

Overview

Journal Neuromolecular Med

Specialty Biochemistry

Date 2016 Sep 21

PMID 27646979

Citations 13

Authors

Pashtun Shahim

Kaj Blennow

Per Johansson

Johan Svensson

Simone Lista

Harald Hampel

Leif Christer Andersson

Henrik Zetterberg

Affiliations

Soon will be listed here.

Abstract

Stanniocalcin-1 (STC-1) is a nerve cell-enriched protein involved in intracellular calcium homeostasis regulation. Changes in calcium regulation are hypothesized to play a role in the pathophysiology of Alzheimer's disease (AD). The expression of STC-1 increases in response to ischemic stroke, but whether it is altered in neurodegenerative disorder, particularly Alzheimer's disease (AD), has not been investigated before. We measured STC-1 in cerebrospinal fluid (CSF) samples from a total of 163 individuals including AD, prodromal AD (pAD), mixed AD, stable mild cognitive impairment (sMCI), and diagnoses of other dementia than AD, as well as cognitively normal controls (CNC) enrolled at academic centers in France and Sweden. STC-1 concentration was reliably measureable in all CSF samples and was significantly increased in the initial exploratory cohort of neurochemically enriched AD patients versus AD biomarker-negative controls. In the second cohort, STC-1 was increased in AD versus pAD, and other dementia disorders, but the difference was not statistically significant. In the third cohort, there was no significant difference in STC-1 concentration between AD and CNC; however, STC-1 concentration was significantly decreased in patients with other dementia disorders compared with AD and CNC. Taken together, CSF STC-1 showed an increasing trend in AD, but the findings were not consistent across the three study cohorts. In contrast, CSF STC-1 concentrations were reduced in patients with dementia diagnoses other than AD, as compared with both AD patients and CNC. The findings from these studies suggest CSF STC-1 as a potential biomarker in differential diagnosis of dementias.

Citing Articles

Emerging insights in senescence: pathways from preclinical models to therapeutic innovations.

Mansfield L, Ramponi V, Gupta K, Stevenson T, Mathew A, Barinda A NPJ Aging. 2024; 10(1):53.

PMID: 39578455 PMC: 11584693. DOI: 10.1038/s41514-024-00181-1.

Transcriptional Patterns in Stages of Alzheimer's Disease Are Cell-Type-Specific and Partially Converge with the Effects of Alcohol Use Disorder in Humans.

Joshi A, Giorgi F, Sanna P eNeuro. 2024; 11(10).

PMID: 39299805 PMC: 11485264. DOI: 10.1523/ENEURO.0118-24.2024.

Emerging phagocytosis checkpoints in cancer immunotherapy.

Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J Signal Transduct Target Ther. 2023; 8(1):104.

PMID: 36882399 PMC: 9990587. DOI: 10.1038/s41392-023-01365-z.

Cellular senescence in cancer: clinical detection and prognostic implications.

Domen A, Deben C, Verswyvel J, Flieswasser T, Prenen H, Peeters M J Exp Clin Cancer Res. 2022; 41(1):360.

PMID: 36575462 PMC: 9793681. DOI: 10.1186/s13046-022-02555-3.

Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer's and other neurodegenerative diseases.

Halbgebauer S, Steinacker P, Riedel D, Oeckl P, Anderl-Straub S, Lombardi J Alzheimers Res Ther. 2022; 14(1):175.

PMID: 36419075 PMC: 9682835. DOI: 10.1186/s13195-022-01122-4.

References

Zhang K, Lindsberg P, Tatlisumak T, Kaste M, Olsen H, Andersson L . Stanniocalcin: A molecular guard of neurons during cerebral ischemia. Proc Natl Acad Sci U S A. 2000; 97(7):3637-42. PMC: 16292. DOI: 10.1073/pnas.97.7.3637. View

Lindsberg P, Roine R, Tatlisumak T, Sairanen T, Kaste M . The future of stroke treatment. Neurol Clin. 2000; 18(2):495-510. DOI: 10.1016/s0733-8619(05)70204-8. View

Serlachius M, Zhang K, Andersson L . Stanniocalcin in terminally differentiated mammalian cells. Peptides. 2004; 25(10):1657-62. DOI: 10.1016/j.peptides.2004.03.031. View

Yoshiko Y, Aubin J . Stanniocalcin 1 as a pleiotropic factor in mammals. Peptides. 2004; 25(10):1663-9. DOI: 10.1016/j.peptides.2004.04.015. View

Ferri C, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M . Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366(9503):2112-7. PMC: 2850264. DOI: 10.1016/S0140-6736(05)67889-0. View

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

Blennow K, de Leon M, Zetterberg H . Alzheimer's disease. Lancet. 2006; 368(9533):387-403. DOI: 10.1016/S0140-6736(06)69113-7. View

Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel S . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(Pt 11):3035-41. DOI: 10.1093/brain/awl269. View

Bostrom F, Hansson O, Gerhardsson L, Lundh T, Minthon L, Stomrud E . CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies. Neurobiol Aging. 2008; 30(8):1265-71. DOI: 10.1016/j.neurobiolaging.2007.10.018. View

10.

Subhash M, Padmashree T, Srinivas K, Subbakrishna D, Shankar S . Calcium and phosphorus levels in serum and CSF in dementia. Neurobiol Aging. 1991; 12(4):267-9. DOI: 10.1016/0197-4580(91)90001-z. View

11.

Blennow K, Hampel H, Weiner M, Zetterberg H . Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. DOI: 10.1038/nrneurol.2010.4. View

12.

Reitz C, Tang M, Schupf N, Manly J, Mayeux R, Luchsinger J . Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol. 2010; 67(12):1491-7. PMC: 3065942. DOI: 10.1001/archneurol.2010.297. View

13.

Johansson P, Mattsson N, Hansson O, Wallin A, Johansson J, Andreasson U . Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis. 2011; 24(3):537-46. DOI: 10.3233/JAD-2011-101878. View

14.

Yeung B, Law A, Wong C . Evolution and roles of stanniocalcin. Mol Cell Endocrinol. 2011; 349(2):272-80. DOI: 10.1016/j.mce.2011.11.007. View

15.

Durukan Tolvanen A, Westberg J, Serlachius M, Chang A, Reddel R, Andersson L . Stanniocalcin 1 is important for poststroke functionality, but dispensable for ischemic tolerance. Neuroscience. 2012; 229:49-54. DOI: 10.1016/j.neuroscience.2012.10.062. View

16.

Khachaturian Z . Calcium, membranes, aging, and Alzheimer's disease. Introduction and overview. Ann N Y Acad Sci. 1989; 568:1-4. DOI: 10.1111/j.1749-6632.1989.tb12485.x. View

17.

Blennow K, Zetterberg H . The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci. 2015; 9:345. PMC: 4586276. DOI: 10.3389/fnins.2015.00345. View

18.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

19.

Masters C, Simms G, Weinman N, Multhaup G, McDonald B, Beyreuther K . Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985; 82(12):4245-9. PMC: 397973. DOI: 10.1073/pnas.82.12.4245. View

20.

Wagner G, Hampong M, Park C, Copp D . Purification, characterization, and bioassay of teleocalcin, a glycoprotein from salmon corpuscles of Stannius. Gen Comp Endocrinol. 1986; 63(3):481-91. DOI: 10.1016/0016-6480(86)90149-8. View